Issn Print: 1356-5524
Publication Date: 2017/08/01
Clinicians should assess the benefits and risks of using bezlotoxumab for reducing the risk of recurrent Clostridium difficile infection
Habiba Hassouna; Abhishek Deshpande
Author Information: Department of Infectious Diseases, Cleveland Clinic, Cleveland, Ohio, USA
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.